IMV stock analysis
IMV (0V11) Share Price & Analysis
0V11 Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- CAD 13.12M
- Enterprise Value
- CAD 41.76M
- Total Cash (Recent Filing)
- CAD 21.21M
- Total Debt (Recent Filing)
- CAD 28.90M
- Price to Earnings (P/E)
- ―
- Beta
- N/A
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
IMV News
0V11 FAQ
What is IMV’s market cap?
When is IMV’s upcoming earnings report date?
How were IMV’s earnings last quarter?
Is IMV overvalued?
Does IMV pay dividends?
What is IMV’s EPS estimate?
What happened to IMV’s price movement after its last earnings report?
Which hedge fund is a major shareholder of IMV?
What is the TipRanks Smart Score and how is it calculated?
Company Description
IMV
IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Andrew Hall
- Employees
- 63
- Website
- www.imv-inc.com
- Address
- 130 Eileen Stubbs Avenue, Dartmouth, NS, B3B 2C4, CA




